Citations

Clear

3485 citation(s) found for "Sy, Sarah".

B7-H4–deficient mice display augmented neutrophil-mediated innate immunity
Zhu, Gefeng, Augustine, Mathew M., Azuma, Takeshi , Luo, Liqun , Yao, Sheng , Anand, Sudarshan , Rietz, A., Huang, Jiaqiang , Xu, Haiying, Flies, Andrew S. , Flies, Sarah J., Tamada, Koji , Colonna, Marco , Deursen, Jan M. A. van, Chen, Lieping , Colonna, Marco

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 8 | Pages: 1759-1767

10.1182/blood-2008-01-133223 | PMID 19109567 Get It

Abstract B7-H4 is an immunoglobulin superfamily molecule and shown to be inhibitory for T-cell responses. To explore physiologic roles of B7-H4, we created B7-H4–deficient (KO) mice by genetic targeting. B7-H4KO mice are healthy and their T- and B-cell responses to polyclonal antigens are in normal range. However, B7-H4KO mice are more resistant to infection by Listeria monocytogenes than their littermates. Within 3 days after infection, bacterial colonies in livers and spleens are significantly lower than the controls, suggesting a role of B7-H4 in enhancing innate immunity. Further studies demonstrate that neutrophils increase in peripheral organs of B7-H4KO mice more so than their littermates but their bactericidal functions remain unchanged. Augmented innate resistance is completely dependent on neutrophils, even in the absence of adaptive immunity. In vitro B7-H4 inhibits the growth of bone marrow–derived neutrophil progenitors, suggesting an inhibitory function of B7-H4 in neutrophil expansion. Our results identify B7-H4 as a negative regulator of the neutrophil response to infection and provide a new target for manipulation of innate immunity.
Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association
Watkins, Janis L., Lewandowski, Katherine T., Meek, Sarah , Störz, Peter , Toker, Alex , Piwnica‐Worms, Helen

Mayo Clinic

Proceedings of the National Academy of Sciences | November 14, 2008 | Volume: 105 | Issue: 47 | Pages: 18378-18383

10.1073/pnas.0809661105 | PMID 19011111 Get It

The Par-1 protein kinases are conserved from yeast to humans, where they function as key polarity determinants. The mammalian Par-1 family is comprised of 4 members (Par-1a, -b, -c, and -d). Previously, we demonstrated that atypical protein kinase C (aPKC) phosphorylates the Par-1 kinases on a conserved threonine residue (T595) to regulate localization and kinase activity. Here, we demonstrate that Par-1b is also regulated by another arm of the PKC pathway, one that involves novel PKCs (nPKC) and protein kinase D. Treatment of cells with the PKC activator phorbol-12-myristate-13-acetate (PMA) potently stimulated phosphorylation of Par-1b on serine 400 (S400), a residue that is conserved in all 4 mammalian Par-1 kinases as well as the fly ortholog. We demonstrate that PMA stimulates nPKC to activate PKD, which in turn directly phosphorylates Par-1b on S400 to positively regulate 14-3-3 binding and to negatively regulate membrane association. Thus, 2 arms of the PKC pathway regulate interactions between Par-1b and 14-3-3 proteins: one involving aPKC and the other nPKC/PKD.
Analysis of the Reaction of Carbachol with Acetylcholinesterase Using Thioflavin T As a Coupled Fluorescence Reporter
Rosenberry, Terrone L. , Sonoda, Leilani K., Dekat, Sarah E., Cusack, Bernadette, Johnson, Joseph L.

Mayo Clinic

Biochemistry | November 12, 2008 | Volume: 47 | Issue: 49 | Pages: 13056-13063

10.1021/bi8015197 | PMID 19006330 Get It

Validation of the Mayo Clinic Risk Score for In-Hospital Mortality After Percutaneous Coronary Interventions Using the National Cardiovascular Data Registry
Milford–Beland, Sarah, Rumsfeld, John S., Spertus, John A. , Singh, Mandeep , Peterson, Eric D. , Spertus, John A

Mayo Clinic

Circulation: Cardiovascular Interventions | August 26, 2008 | Volume: 1 | Issue: 1 | Pages: 36-44

10.1161/circinterventions.107.755991 | PMID 20031653 Get It

Background— We sought to validate the recently developed Mayo Clinic Risk Score model for in-hospital mortality after percutaneous coronary intervention using an independent data set. The Mayo Clinic Risk Score has 7 simple clinical and noninvasive variables, available before coronary angiography, for prediction of in-hospital mortality. External validation using an independent data set would support broader applicability of the model. Methods and Results— In-hospital mortality after percutaneous coronary intervention on 309 351 patients from the National Cardiovascular Data Registry admitted from January 1, 2004, to March, 30, 2006, was studied. Using the Mayo Clinic Risk Score equation, we assigned predicted probabilities of death to each patient. The area under the receiver-operating characteristics curve was 0.884, indicating excellent discrimination overall as well as among subgroups, including gender, diabetes mellitus, renal failure, low ejection fraction, different age groups, and multivessel disease. Ninety-seven percent of patients undergoing percutaneous coronary intervention had a Mayo Clinic Risk Score <10, indicating low to intermediate risk. The Mayo Clinic Risk Score model initially slightly underpredicted event rates when applied in National Cardiovascular Data Registry data (observed 1.23% versus predicted 1.10%), but this underprediction was corrected after recalibration. The recalibrated risk score discriminated (c index=0.885) and calibrated well in an National Cardiovascular Data Registry validation data set consisting of procedures performed between April 1, 2006, and March 30, 2007. Conclusions— Seven variables can be combined into a convenient risk scoring system before coronary angiography is performed to predict in-hospital mortality after percutaneous coronary intervention. This model may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process before percutaneous coronary intervention.
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007
Bronstein, Jeff M. , Carvey, Paul M., Chen, Honglei , Cory‐Slechta, Deborah A. , Monte, Donato A. Di , Duda, John E. , English, Paul , Goldman, Samuel M. , Grate, Stephen J., Hoppin, Jane A. , Jewell, Sarah A. , Kamel, Freya , Langston, J. William, Logroscino, Giancarlo , Nelson, Lorene M. , Ravina, Bernard, Rocca, Walter A. , Ross, G. Webster, Schettler, Ted, Schwarzschild, Michael A. , Scott, Bill, Seegal, Richard F., Singleton, Andrew , Steenland, Kyle , Eeden, Stephen Van Den, Weisskopf, Marc G. , Hansen, Johnni , Koroshetz, Walter J. , Tanner, Caroline M. , Logroscino, Giancarlo

Mayo Clinic

Environmental Health Perspectives | August 25, 2008 | Volume: 117 | Issue: 1 | Pages: 117-121

10.1289/ehp.11702 | PMID 19165397 Get It

Abstract Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder. People with PD, their families, scientists, health care providers, and the general public are increasingly interested in identifying environmental contributors to PD risk. Methods In June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, USA, to assess what is known about the contribution of environmental factors to PD. Results We describe the conclusions around which they came to consensus with respect to environmental contributors to PD risk. We conclude with a brief summary of research needs. Conclusions PD is a complex disorder, and multiple different pathogenic pathways and mechanisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, and within populations, the causes of PD are heterogeneous. Although rare recognized genetic mutations are sufficient to cause PD, these account for &lt; 10% of PD in the U.S. population, and incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay among environmental factors and genetic makeup likely influences the risk of developing PD. There is a need for further understanding of how risk factors interact, and studying PD is likely to increase understanding of other neurodegenerative disorders.
P1‐106: LRRK2 as a common link between tauopathies and synucleinopathies
Melrose, Heather L. , Lincoln, Sarah, Lewis, Jada , Miles, Sarah J. , Knight, Joshua A. , Farrer, Matthew J.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2008.05.693 Get It

The Effects of Survey Mode and Asking About Future Intentions on Self-Reports of Colorectal Cancer Screening
Beebe, Timothy J. , Jenkins, Sarah M. , Anderson, Kari J., Davern, Michael E., Rockwood, Todd

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 8, 2008 | Volume: 17 | Issue: 4 | Pages: 785-790

10.1158/1055-9965.epi-07-2622 | PMID 18381470 Get It

Abstract Colorectal cancer (CRC) screening rates are often ascertained via self-reports but can be subject to overreporting bias. Asking about intention to get screened before asking about past screening may minimize overreporting of cancer screening. In a statewide survey conducted from July through October of 2005, we embedded an experiment that tested the effect of question ordering (asking about future intention to get screened before or after asking about past screening; “future first” and “future second,” respectively), crossed with survey mode (mail versus telephone), on CRC screening rates. Weighted analysis focused on 752 respondents who were ages 50 years or older. We found (a) that asking about future intentions to get screened before asking about past screening (future first) statistically significantly lowers reports of past CRC screening [70.9% future second versus 58.0% future first; odds ratio (OR), 1.83; 95% confidence interval (95% CI), 1.08-3.13]; (b) that there was no main effect of survey mode; and (c) that the effect of the ordering of the future intentions item varies by survey mode. In the mailed survey, the odds of reporting past CRC screening were almost thrice greater in the future second condition compared with the future first condition (72.4% versus 49.0%, respectively; OR, 2.74; 95% CI, 1.22-6.17). In the telephone condition, the odds of reporting were only 28% higher in the future second (69.5%) condition than in the future first condition (63.9%; OR, 1.28; 95% CI, 0.64-2.57). The results suggest that asking about future intentions to get screened before the actual behavior elicits lower, and arguably more truthful reports of CRC screening but mainly in mailed surveys. (Cancer Epidemiol Biomarkers Prev 2008;17(4):785–90)
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, Chitta Ranjan , Wang, Enfeng , Katarya, Aaron, Lau, Julie S., Dutta, Shamit K., Muders, Michael H. , Wang, Shanfeng , Buhrow, Sarah A. , Safgren, Stephanie L. , Yaszemski, Michael J. , Ames, Matthew M. , Bhattacharya, Resham , Reid, Joel M. , Mukherjee, Priyabrata , Mukhopadhyay, Debabrata , Safgren, Stephanie L

Mayo Clinic

Cancer Research | March 13, 2008 | Volume: 68 | Issue: 6 | Pages: 1970-1978

10.1158/0008-5472.can-07-6102 | PMID 18339879 Get It

Abstract One of the key challenges in anticancer therapy is the toxicity and poor bioavailability of the anticancer drugs. Nanotechnology can play a pivotal role by delivering drugs in a targeted fashion to the malignant cells that will reduce the systemic toxicity of the anticancer drug. In this report, we show a stepwise development of a nanoparticle-based targeted delivery system for in vitro and in vivo therapeutic application in pancreatic cancer. In the first part of the study, we have shown the fabrication and characterization of the delivery system containing gold nanoparticle as a delivery vehicle, cetuximab as a targeting agent, and gemcitabine as an anticancer drug for in vitro application. Nanoconjugate was first characterized physico-chemically. In vitro targeting efficacy, tested against three pancreatic cancer cell lines (PANC-1, AsPC-1, and MIA Paca2) with variable epidermal growth factor receptor (EGFR) expression, showed that gold uptake correlated with EGFR expression. In the second part, we showed the in vivo therapeutic efficacy of the targeted delivery system. Administration of this targeted delivery system resulted in significant inhibition of pancreatic tumor cell proliferation in vitro and orthotopic pancreatic tumor growth in vivo. Tumor progression was monitored noninvasively by measuring bioluminescence of the implanted tumor cells. Pharmacokinetic experiments along with the quantitation of gold both in vitro and in vivo further confirmed that the inhibition of tumor growth was due to targeted delivery. This strategy could be used as a generalized approach for the treatment of a variety of cancers characterized by overexpression of EGFR. [Cancer Res 2008;68(6):1970–8]
Accuracy of Diagnostic Tests for Cushing’s Syndrome: A Systematic Review and Metaanalyses
Elamin, Mohamed B., Murad, M. Hassan , Mullan, Rebecca J., Erickson, Dana , Harris, Katherine , Nadeem, Sarah , Ennis, Robert, Erwin, Patricia J., Montori, Víctor M. , Murad, M Hassan , Montori, Victor M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 12, 2008 | Volume: 93 | Issue: 5 | Pages: 1553-1562

10.1210/jc.2008-0139 | PMID 18334594 Get It

Abstract Context: The diagnosis of Cushing’s syndrome (CS) requires the use of tests of unregulated hypercortisolism that have unclear accuracy. Objective: Our objective was to summarize evidence on the accuracy of common tests for diagnosing CS. Data Sources: We searched electronic databases (MEDLINE, EMBASE, Web of Science, Scopus, and citation search for key articles) from 1975 through September 2007 and sought additional references from experts. Study Selection: Eligible studies reported on the accuracy of urinary free cortisol (UFC), dexamethasone suppression test (DST), and midnight cortisol assays vs. reference standard in patients suspected of CS. Data Extraction: Reviewers working in duplicate and independently extracted study characteristics and quality and data to estimate the likelihood ratio (LR) and the 95% confidence interval (CI) for each result. Data Synthesis: We found 27 eligible studies, with a high prevalence [794 (9.2%) of 8631 patients had CS] and severity of CS. The tests had similar accuracy: UFC (n = 14 studies; LR+ 10.6, CI 5.5–20.5; LR− 0.16, CI 0.08–0.33), salivary midnight cortisol (n = 4; LR+ 8.8, CI 3.5–21.8; LR− 0.07, CI 0–1.2), and the 1-mg overnight DST (n = 14; LR+ 16.4, CI 9.3–28.8; LR− 0.06, CI 0.03–0.14). Combined testing strategies (e.g. a positive result in both UFC and 1-mg overnight DST) had similar diagnostic accuracy (n = 3; LR+ 15.4, CI 0.7–358; LR− 0.11, CI 0.007–1.57). Conclusions: Commonly used tests to diagnose CS appear highly accurate in referral practices with samples enriched with patients with CS. Their performance in usual clinical practice remains unclear.